Rank #1960FULC

Fulcrum Therapeutics, Inc.

$11.73

7.22% (Daily)

Market Cap

$773.83M

Revenue

$N/A

Rank by MCap

#1960

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Alexander C. Sapir

Headquarters

Cambridge, MA

Employees

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, s...